Detailed data from the first Phase III trial of Human Genome Sciences Inc.'s lupus drug Benlysta (belimumab) lived up to expectations, boosting analyst confidence in the outcome of a second Phase III trial to be revealed Nov. 2. (BioWorld Today) Read More
No AbstractIpsen SA has licensed rights to gout drug Adenuric - the first gout drug approved in four decades - in 41 countries to the Menarini Group in a deal that gives Ipsen €132 million (US$197 million).Paris-based Ipsen will received €20 million up front, and retains co-marketing rights in France, where the companies will split market costs and profits, plus royalties in the low-teens on Menarini's net sales. Read More
